Jiong Wu

ESAM reduces sensitivity to anti-HER2 therapy in HER2-positive breast cancer by activating the mTOR pathway

Abstract Despite improved survival rates with dual trastuzumab and pertuzumab therapy, patients with HER2-positive breast cancer frequently experience disease progression due to intrinsic or acquired resistance. Elucidating the underlying mechanisms of resistance and identifying...